Clinical Consequences of Aspergillus Disease in Cystic Fibrosis

  • Research type

    Research Study

  • Full title

    Clinical Consequences of Aspergillus Colonisation and Disease in Cystic Fibrosis and the Role of Environment in Acquisition and Infection

  • IRAS ID

    232722

  • Contact name

    Lisa Collier

  • Contact email

    lisa.collier@mft.nhs.uk

  • Sponsor organisation

    Manchester University NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 8 months, 3 days

  • Research summary

    Aspergillus is a common fungal pathogen found in the environment, and cystic fibrosis patient's lungs are particularly vulnerable to infection. This study aims to determine the clinical consequences of Aspergillus colonisation and disease in cystic fibrosis patients. A previous study (REC reference number 07/Q1403/70) suggested 4 classifications of Aspergillus disease in cystic fibrosis, and those same patients will be followed up for the first time to determine clinical outcomes and clinical decline in each class of disease. The surviving patients will then be retyped with blood and sputum samples to see if they have changed their type of disease over time.
    The study will also investigate the role of environmental and ventilation factors in the acquisition of Aspergillus disease, looking at current environmental data from the cystic fibrosis unit and prospectively from the patient's home environments.

  • REC name

    North West - Greater Manchester South Research Ethics Committee

  • REC reference

    18/NW/0144

  • Date of REC Opinion

    27 Feb 2018

  • REC opinion

    Favourable Opinion